DXCM DEXCOM INC.

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

(NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024.

The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast.

Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit .

Category: IR

EN
19/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

 PRESS RELEASE

Dexcom Reports First Quarter 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $101.1 million or 11.0% of revenue, an increase of 460 basis points compared to the first quarter of 2023...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dexcom Inc: 1 director

A director at Dexcom Inc sold 49,633 shares at 138.298USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

Dexcom Publishes Annual Sustainability Report

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy. “We are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We see an inherent connection betw...

 PRESS RELEASE

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Ca...

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-1647...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch